Patents for A61P 35 - Antineoplastic agents (221,099)
01/2005
01/04/2005US6838279 DNA having a deletion in both copies of the LAT gene and ICP34.5 gene are inserted into the malignant cell
01/04/2005US6838269 Comprises reduced allergenic variant of enzymatic polypeptide for use in textile treatment and cleaning composition and animal feeds; antiallergens
01/04/2005US6838261 Nucleic acids encoding anti-CD40 proteins and methods of producing recombinant anti-CD40 proteins
01/04/2005US6838093 System for osmotic delivery of pharmaceutically active agents
01/04/2005US6838086 Comprises dendritic cells; for production of vaccines; anticancer agents
01/04/2005US6838073 Cobalamin conjugates useful as imaging and therapeutic agents
01/04/2005CA2301503C Pharmaceutical compositions for oral administration of molecular iodine
01/04/2005CA2283509C Novel bicyclonucleoside and oligonucleotide analogue
01/04/2005CA2255637C Conjugates of cis-docosahexaenoic acid and paclitaxel
01/04/2005CA2151730C New crystalline form of a vitamin d analogue
01/01/2005CA2472846A1 Methods for assessing and treating leukemia
12/2004
12/30/2004US20040268425 use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes; transgenic animals; dosage forms
12/30/2004US20040267028 Such as 2-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide hydrochloride
12/30/2004US20040267012 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
12/30/2004US20040266882 Administering chemotherapeutically effective amount of at least one chemotherapeutic agent and a chemosensitizing effective amount of at least one 3-aryloxy-3-phenylpropylamine such as 3-(p-isopropoxyphenoxy)-3-phenylpropylamine methanesulfonate; advantageous in treatment of multidrug resistance cancer
12/30/2004US20040266873 1-butane acid derivatives pharmaceutical compositions containing said derivatives and the use thereof
12/30/2004US20040266868 Triterpenoid derivatives
12/30/2004US20040266855 Effective against Src family; cancer, osteoporosis
12/30/2004US20040266853 Small molecule antiproliferative agents
12/30/2004US20040266847 Biologically active neopeltolide compounds
12/30/2004US20040266841 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity
12/30/2004US20040266839 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors
12/30/2004US20040266826 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
12/30/2004US20040266815 Alzheimer's disease, bipolar disorder, diabetes, dementia, stroke, schizophrenia, depression, hair loss, cancer
12/30/2004US20040266810 Metabolites of tricyclic amides useful for inhibition of G-protein function and methods of treatment of proliferative diseases
12/30/2004US20040266809 Method of treating multiple myeloma
12/30/2004US20040266797 Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
12/30/2004US20040266793 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
12/30/2004US20040266780 Inhibitors of human phosphatidyl-inositol 3-kinase delta
12/30/2004US20040266779 Use of c-kit inhibitors for the treatment of myeloma
12/30/2004US20040266777 Pyridopyrazines and the use thereof as kinase inhibitors
12/30/2004US20040266775 for human, veterinary, or phytoprotective use, e.g., inhibiting the cellular sodium-proton antiporter activity, for the treatment of cardiovascular diseases, metabolic diseases, cancerous diseases or fibrotic diseases
12/30/2004US20040266773 Such as 4-(3-methoxyphenyl)-5-methyl-6-(2-fluorobenzyl)-2-(N-(2-pyridyl)ethyl-N -methyl)ethyl-pyridazin-3-one; drugs/prodrugs for treatment of sex-hormone related conditions in men/women
12/30/2004US20040266770 treating diseases that are triggered by persistent angiogenesis; inhibition of the VEGF receptor
12/30/2004US20040266766 Selective urokinase inhibitors
12/30/2004US20040266765 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
12/30/2004US20040266764 Hydroxamic acid derivatives
12/30/2004US20040266753 Benzo[a]pyrano[3,2-h]acridin-7-one compounds
12/30/2004US20040266750 Beta-lactamyl vasopressin v1aantagonists
12/30/2004US20040266747 Long chain fatty alcohol substituents in antineoplastic agents
12/30/2004US20040266746 the sensitivity of cells typical of various proliferative disorders to the ansamycin CNF-101 ("17-AAG") is proportional to the HER-2 levels in those cells
12/30/2004US20040266733 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1)
12/30/2004US20040266726 yeast-derived ingredient having beta 1,3/1.6 glucan structure (IMMUTOL) or Norwegian Beta Glucan (TM); natural killer cell activating capabilities and tumor angiogenesis inhibiting capability by oral administration
12/30/2004US20040266723 Antiviral agents for treatment of Flaviviridae infections
12/30/2004US20040266720 Splice-region antisense composition and method
12/30/2004US20040266719 immunostimulatory CpG oligonucleotide for inducing a mucosal immune response for treating a subject having an infection comprising enterovirus, calciviridae, vesicular stomatitis, rotavirus infection, Salmonella spp. infection, Helicobacter pyloris infection and M. intracellulare infection
12/30/2004US20040266710 Immunotherapy; induce immunology response
12/30/2004US20040266709 Immunotherapy; induction immunology response
12/30/2004US20040266704 Therapy for drug resistant cancer
12/30/2004US20040266695 Novel LHRH antagonists having improved solubility properties
12/30/2004US20040266694 Angiogenesis inhibitor induced by vascular endothelial growth factor
12/30/2004US20040266687 Antiproliferative agents; antiinflammatory agents; angiogenesis inhibitors; anticancer agents
12/30/2004US20040266686 Administering endothelial growth factor antagonist; wound healing agents
12/30/2004US20040266679 Isolated ucleic acid; nucleotide sequence coding protein; detection moderators of kinase peptide
12/30/2004US20040266676 Preventives/remedies for proliferative organ diseases chronic arthritic diseases. hypertrophic scar or keloid
12/30/2004US20040266674 For diagnosis, therapy, prevention of cell proliferation, autoimmune disease, antiinflammatory agents, cardiovascular disorders, central nervous system disorders; isolated nucleic acids; genetic engineeringo
12/30/2004US20040266665 Therapy for thyroid disease; anticancer agents; metabolitic and reproductive diseases
12/30/2004US20040265972 Modified human chorionic gonadotropin (CG) for use in treatment and prevention of metabolic and reproductive diseases
12/30/2004US20040265968 Tissue plasminogen activator-like protease
12/30/2004US20040265913 Tumor necrosis factors (TNF); humanized/chimeric monoclonal antibodies; fab fragments; hybridomas, host cells, Chinese Hamster Ovary cells
12/30/2004US20040265898 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
12/30/2004US20040265891 use in diagnosis and treatment of cancer, neurodegenerative, or immune disorders; antibodies for immunoassays; drug screening
12/30/2004US20040265890 a polypeptide of given amino acid sequence; use as drug target for gastrointestinal disorders; fusion proteins; diagnosis
12/30/2004US20040265885 Peptide nucleic acid (PNA) derivatives which carry one or more phosphoryl radicals at the N terminus of the PNA backbone; can be purified using efficient methods such as chromatography or electrophoresis; use as pharmaceuticals and diagnostic agents
12/30/2004US20040265807 Enzymes
12/30/2004US20040265804 Method for identifying metastatic tumor cells
12/30/2004US20040265803 for the prevention, diagnosis and/or therapy of MSI+ tumors; antibodies against the gene product; use as antitumor agents or vaccines
12/30/2004US20040265791 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
12/30/2004US20040265787 Immortalized human keratinocyte cell line
12/30/2004US20040265404 plant extracts containig flavonoids such as gallic acid, epigallocatechin gallate or epicatechin gallate used as drugs, nutraceuticals or in foods
12/30/2004US20040265392 Nanoparticles comprising biologically active tnf which is immobilized on the same
12/30/2004US20040265382 Methylsulfonylphenyl or phenylsulfonamide derivatives having ring selected from cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine; celecoxib and rofecoxib; administered for pain; oral drug delivery
12/30/2004US20040265376 Orally deliverable; enhanced bioavailability; encapsulated in dissolution resistant material
12/30/2004US20040265350 Ceramic carrier comprising interconnected skeleton of scaffolding and struts having pores; low density; time-release agents; fibroblast-, or transforming growth factors; bone morphogenic proteins, somatotrophin; antibiotics, vitamins, proteins, hormones, radiopacity agents
12/30/2004US20040265317 Methods and compositions useful for inhibition of angiogenesis
12/30/2004US20040265316 An antibody which specifically binds to a Fhit (fragile histidine triad) protein or derivative
12/30/2004US20040265311 Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity
12/30/2004US20040265309 Method of tumor regression with VEGF inhibitors
12/30/2004US20040265307 Anti-IGF-I receptor antibody
12/30/2004US20040265300 Targeting cancer cell; induction or prevention of apoptosis in eukaryotic cells; a fusion peptide contains a viral apoptotic peptide and an antibody fragment; recombinant host cell comprising the vector, encoding chimeric polypeptide; bioassay monitoring apoptosis activity; drug target
12/30/2004US20040265284 Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains
12/30/2004US20040265281 System capable of treating and defining various diseases using stem cells
12/30/2004US20040265277 Agents for treating malignant diseases using the protein YB-1
12/30/2004US20040265273 gene therapy; nucleic acid sequence encoding an amino terminal fragment of urokinase that comprises and epidermal growth factor-like domain; antimetastasis; murine urokinase ATF expressed by tumor cells in an athymic murine model unexpectedly effectively inhibits tumorigenicity
12/30/2004US20040265272 Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof
12/30/2004US20040265271 Reovirus for the treatment of neoplasia
12/30/2004US20040265270 recombinant; Interferons; stabilized with a polyol, a non-reducing sugar or a amino acid; acetate buffer, albumin; mannitol, saccharose and glycine; storage stability
12/30/2004US20040265228 biomarkers for medicinal radioimaging such as Positron Emission Tomography; 4-Anilinoquinazolines
12/29/2004WO2004113562A1 Method for assaying lkb1 phosphorylation activity
12/29/2004WO2004113388A2 Anti alpha - folate - receptor - tetramer antibodies
12/29/2004WO2004113381A1 Relaxin superfamily peptide analogues
12/29/2004WO2004113366A1 Histone deacetylase inhibitor and process for producing the same
12/29/2004WO2004113336A1 Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
12/29/2004WO2004113335A2 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
12/29/2004WO2004113331A1 Novel compounds that modulate pparϝ type receptors, and use thereof in cosmetic or pharmaceutical compositions
12/29/2004WO2004113324A1 Chinazoline derivatives as aurora kinase inhibitors
12/29/2004WO2004113318A1 Flavanone compound and uses thereof
12/29/2004WO2004113304A1 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
12/29/2004WO2004113300A1 Novel tricyclic heterocycle compound
12/29/2004WO2004112839A2 Specific high-relaxivity conjugate compounds for magnetic resonance imaging